nutch_noindex
CANCELAR
COVID-2019 Alert

Information about the 2019 Novel Coronavirus. Read the latest >

Información sobre el coronavirus 2019 (COVID-19). Aprenda más >

/nutch_noindex

Brita Mittal, MD

  • No hay imagen

Especialidades médicas y/o especialidades quirúrgicas

Anesthesia

Trabajo y educación

Educación

UCLA GME Office, Los Angeles, CA, 6/1/2012

Primeros años de residencia

Stanford University Internal Medicine Residency, Stanford, CA, 6/24/2013

Últimos años de residencia

Stanford University Anesthesiology Residency, Stanford, CA, 6/30/2016

Subespecialidad

Stanford University Anesthesiology Fellowships, Stanford, CA, 07/31/2017

Certificado(s) de especialidad

Anesthesia, American Board of Anesthesiology

Todo Publicaciones

The Safety and Efficacy of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange for Laryngologic Surgery. The Laryngoscope Nekhendzy, V. n., Saxena, A. n., Mittal, B. n., Sun, E. n., Sung, K. n., Dewan, K. n., Damrose, E. J. 2020

Abstract

Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) is an intraoperative ventilatory technique that allows avoidance of tracheal intubation (TI) or jet ventilation (JV) in selected laryngologic surgical cases. Unimpeded access to all parts of the glottis may improve surgical precision, decrease operative time, and potentially improve patient outcomes. The objective of this prospective, randomized, patient-blinded, 2-arm parallel pilot trial was to investigate the safety and efficacy of THRIVE use for adult patients undergoing nonlaser laryngologic surgery of short-to-intermediate duration.Twenty adult, American society of anesthesiology class 1-3 patients with body mass index (BMI)<35kg/m2 were randomly assigned to either an experimental THRIVE group or active comparator conventional ventilation group (TI or supraglottic high-frequency JV [SHFJV]). Primary outcomes included intraoperative oxygenation, anesthesia awakening/extubation time, time to laryngoscopic suspension, number of intraoperative suspension adjustments, and operative time. Secondary patient outcomes including postanesthesia and functional patient recovery were investigated.Compared to TI/SHFJV, THRIVE use was associated with significantly lower intraoperative oxygenation (SpO2 93.05.6% vs. 98.71.6%), shorter time to suspension (1.81.1minutes vs. 4.32.1minutes), fewer suspension adjustments (0.40.5 vs. 1.70.9), and lower postoperative pain scores on recovery room admission (1.31.9 vs. 3.72.9) and discharge (0.91.3 vs. 2.71.8). The study was underpowered to detect other possible outcome differences.We confirm the safe intraoperative oxygenation profile of THRIVE for selected patients undergoing nonlaser laryngologic surgery of short-to-intermediate duration. THRIVE facilitated surgical exposure and improved early patient recovery, suggesting a potential economic benefit for outpatient laryngologic procedures. The results of this exploratory study provide a framework for designing future adequately powered THRIVE trials.ClinicalTrials.gov (NCT03091179).II Laryngoscope, 2020.

View details for DOI 10.1002/lary.28562

View details for PubMedID 32078170